Naia was founded by a team of experienced biopharmaceutical executives who have a proven track record in drug development, product sourcing, global operations and business transactions.
H Daniel Perez MD
Co-Founder, CEO and Chairman
During his twenty-three years in the pharmaceutical industry, Dr Perez has developed wide-ranging experience driving R&D operations, clinical trials, collaborations, licensing deals, spin-outs and acquisitions. He has published extensively and has been elected to multiple scientific societies and nominated to the National Academy of Sciences, in addition to serving on numerous Boards of Directors, Scientific Advisory Boards and Investment Boards, both commercial and academic.
Dr Perez received his medical degree in Buenos Aires, Argentina and completed his medical training at Beth Israel-Mount Sinai in New York and a fellowship in rheumatology and immunology at New York University. He went on to serve on the faculty at New York University as an assistant professor of medicine and at UCSF as a professor of medicine.
Co-Founder, CFO and COO
Mr Bagnall has held c-suite positions in public and private biotechnology companies for more than 20 years. During that time, he negotiated and managed five M&A transactions, raised more than $250 million in equity and debt financings and negotiated numerous licensing agreements.
Prior to co-founding Naia, Mr. Bagnall was chief financial officer of several public and private biotechnology companies and was responsible for many public and private financings, mergers and licensing transactions.
He was also one of the founders the Association of Bioscience Financial Officers, an international organization of life science CFOs. He is a CPA and started his career in the high technology/biotechnology practice of Ernst & Young.
David Chernoff MD
Chief Medical Officer
Dr Chernoff has 25 years experience in bioscience. During that time he has served at CMO, Vice-President and Senior Advisor level for numerous pharmaceutical companies, encompassing established international organizations and start-ups where, in addition to providing medical guidance and expertise, Dr Chernoff took a lead role in the evaluation of a broad range of in-licensing opportunities.
He was subsequently actively involved in conducting due diligence and incubating new companies as an operating partner with venture firm, TPG.
Dr. Chernoff received a BS in biology from Yale University and an MD from New York University. He completed his medical training in internal medicine, rheumatology and infectious disease at the University of California, San Francisco.
Board of Directors
Dr Sherine Helmy
Dr Sherine Helmy has 30 years of experience in the pharmaceutical industry and is the chief executive officer of Pharco Pharmaceuticals, in addition to serving on various other Boards, both commercial and academic.
Dr Omar Haffar PhD
Dr Omar Haffar PhD is a cell biologist with 28 years of experience in the biotechnology industry and is the president and chief executive officer of Eos Biosciences Inc, in addition to serving on the Naia Board of Directors.
Robert Williamson III
Robert F Williamson III is the CEO of privately held PharmAkea, a company involved in the development of fibrosis and oncology drugs, in addition to serving on the Naia Board of Directors.
Board of Advisors
Dr Jorge Puente MD
Dr Jorge Puente MD serves as chairman of Naia’s Board of Business Advisors. He has extensive experience in all areas of pharmaceutical development and financing and is also recognized internationally for his humanitarian work.
Dr Ed Pezalla MD
Dr Pezalla MD is a national and international public policy, public affairs and healthcare innovations leader who is active in helping inform and shape systems and policy frameworks in the US, in addition to serving on Naia’s Board of Advisors.
Lord Edward (Tim) Razzall CBE
Lord Razzall has more than 35 years of corporate finance experience in multinational and cross border transactions. He serves on numerous Boards and is currently the co-chairman of the Parliamentary Committee for Treasury matters in the UK.
Robert Williamson III
Robert F Williamson III is the CEO of privately held PharmAkea, a company involved in the development of fibrosis and oncology drugs. He is a member of the Naia Board of Advisors, in addition to serving on the Naia Board of Directors.